VEGFA and glioblastoma: However, in CheckMate 143 (NCT02017717), the first clinical trial of PD pathway inhibition in GBM, nivolumab failed to prolong the OS of recurrent GBM patients compared with the anti-VEGF antibody bevacizumab 113.